

Human DLL4 ELISA Kit | DLL4 elisa kit

Human DLL4 ELISA Kit

CATALOG #
AAA259537

REACTIVITY
Human


PRODUCT SYNONYMS

DLL4; Human DLL4 ELISA Kit; Human DLL4/Delta-like 4 ELISA Kit; delta-like 4 (Drosophila); AOS6 ELISA Kit; Human; delta4 ELISA Kit; hdelta2 ELISA Kit; UNQ1895/PRO4341 ELISA Kit; DLL4 elisa kit

PRODUCT SPECIFICATIONS

Reactivity	Human
Specificity	This assay recognizes recombinant Human DLL4.
Assay Type	Solid Phase Sandwich ELISA (quantitative)
Detection Range	1562.5-100000pg/ml
Sensitivity	32.1pg/mL
Notes	The kit has been verified by high purity Human DLL4/Delta-like 4 recombinant protein
Preparation and Storage	Unopened Kit: Store at 2-8 degree C Opened/Reconstituted Reagents: Please refer to CoA This ELISA Kit is shipped at ambient temperature.

IMAGES



Application Data

This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.

ADDITIONAL INFORMATION

Related Product Information for DLL4 elisa kit	This Human DLL4 ELISA Kit is an enzyme-linked immunosorbent assay for the quantitative measurement of Human DLL4 protein in Cell supernatant. It contains recombinant Human DLL4, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use. Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.
Product Categories/Family for DLL4 elisa kit	Cancer Drug Targets Notch Pathway
References	Ya. M. e. al. (2007). Delta-lik. 4/Notc. signalin. an. it. therapeuti. implications. Cli. Cance. Res. 13(24). 7243-6. Sainso. RC. e. al. (2007). Anti-Dll. therapy. ca. w. bloc. tumou. growt. b. increasin. angiogenesis. Trend. Mo. Med. 13(9). 389-95. Martine. JC. e. al. (2009). Nuclea. an. membran. expressio. o. th. angiogenesi. regulato. delta-lik. ligan. . (DLL4. i. norma. an. malignan. huma. tissues. Histopathology. 54(5). 598-606. L. JL. e. al. (2010). Targetin. DLL. i. tumor. show. preclinica. activit. bu. potentiall. significan. toxicity. Futur. Oncol. 6(7). 1099-103.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://www.aaabiotech.com/human-elisa-kits/dll4/259537>